Bill Facteau bought $25k of BCDA
director at BioCardia, Inc.. 13,123 shares at an average of $1.91, traded Apr 23, 2025, filed Apr 25, 2025.
Score components
- +15RoleDirector
- 0Trade size$25k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context6% above the 52-week low; 40% below the 52-week high
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m 0.0%, 3m +19.3%, 6m -29.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-013199, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | POpen-market purchase Common Stock | +13,123 | $1.91 | $25k | 13,123 | Apr 25, 2025 |
| Apr 23, 2025 | POpen-market purchase Warrant (right to buy)derivative | +13,123 | - | - | 13,123 | Apr 25, 2025 |
Related signals
Other insiders at BioCardia, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,030 1,000 shares | +0% | |
| 33Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,995 1,900 shares | +0% | |
| 28Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $872 800 shares | +0% | |
| 51Moderate | BioCardia, Inc. | Simon H Stertzer director | $104k 109,200 shares | +191% | |
| 41Moderate | BioCardia, Inc. | Peter Altman President and CEO | $2,043 2,300 shares | +1% | |
| 56Moderate | BioCardia, Inc. | Peter Altman President and CEO | $4,250 5,000 shares | +2% | |
| 43Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,570 1,700 shares | +1% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,244 5,700 shares | +2% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,202 5,100 shares | +2% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,550 5,000 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.